<?xml version='1.0' encoding='iso-8859-1'?>
<newsitem date="1997-05-07" id="root" itemid="565213" xml:lang="en">
<title>USA: Interferon completes Phase III enrollment.</title>
<headline>Interferon completes Phase III enrollment.</headline>
<dateline>NEW BRUNSWICK, N.J. 1997-05-07</dateline>
<text>
<p>Interferon Sciences Inc said Wednesday that it has reached the enrollment target of 110 patients in its Phase III, multi-center clinical trial investigating the potential use of ALFERON N Injection for the treatment of HIV-positive patients.</p>
<p>The company said that if the results of the 24-week treatment phase are favorable, it anticipates seeking U.S. Food and Drug approval of ALFERON N Injection for the treatment of HIV-positive patients in the first quarter of 1998.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<dc element="dc.date.created" value="1997-05-07" />
<dc element="dc.publisher" value="Reuters Holdings Plc" />
<dc element="dc.date.published" value="1997-05-07" />
<dc element="dc.source" value="Reuters" />
<dc element="dc.creator.location" value="NEW BRUNSWICK, N.J." />
<dc element="dc.creator.location.country.name" value="USA" />
<dc element="dc.source" value="Reuters" />
</metadata>
</newsitem>